Clinical trial
506U78 in Treating Patients With Refractory Hematologic Cancer
NCT00002970 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00002970 |
|---|---|
| Title | 506U78 in Treating Patients With Refractory Hematologic Cancer |
| Official title | A Phase II Study of Compound 506U78 in Patients With Refractory T-Cell Malignancies-POG/CCG Intergroup Study |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Children's Cancer Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia |
| Intervention type | Drug |
| Interventions | nelarabine, methotrexate, cytarabine, therapeutic hydrocortisone |
| Enrollment | 148 |
| Start date | Jun 1, 1997 |
| Primary completion | Jan 1, 2005 |
| First posted | Aug 11, 2003 |
| Last update posted | Jul 2, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: